---

Homeostasis: Definition and Components

(15-Mark MBBS Answer)

---

DEFINITION

• Claude Bernard (1878) first described the concept of milieu intérieur (internal environment) - the extracellular fluid (ECF) bathing all tissue cells. He stated that "the constancy of the internal environment is the condition for free, independent life."
• Walter B. Cannon (1932) coined the term homeostasis to describe "the various physiologic arrangements which serve to restore the normal state, once it has been disturbed."

• Medical Physiology (Boron & Boulpaep)

---

WHY IS HOMEOSTASIS IMPORTANT?

1. All cells of the body live in the ECF (milieu intérieur) - not in the outside world.
2. Enzymes, ion channels, and cellular processes function only within narrow ranges of pH, temperature, and electrolyte concentrations.
3. Even small deviations - e.g., plasma K+ rising from 4 mEq/L to 7 mEq/L - can be lethal.
4. Homeostasis allows organisms to live in hostile external environments; without it, life is impossible for complex multicellular organisms.

---

COMPONENTS OF HOMEOSTASIS

---

1. STIMULUS / VARIABLE (Controlled Parameter)

• The factor being regulated - e.g., blood glucose, body temperature, blood pressure, plasma pH.
• A change (perturbation) in the controlled variable from its normal value triggers the homeostatic response.
• Example: Blood glucose rising after a meal is the stimulus.

---

2. RECEPTOR / SENSOR

• A structure (cell, organ, or receptor molecule) that detects the change in the controlled variable.
• It monitors the internal environment continuously.
• Sends information about the current state of the variable to the control center.
• Examples:
  • Baroreceptors in the carotid sinus and aortic arch detect changes in blood pressure.
  • Chemoreceptors in the carotid and aortic bodies detect changes in PO2, PCO2, pH.
  • Osmoreceptors in the hypothalamus detect changes in plasma osmolality.
  • Beta cells of the pancreatic islets act as sensors for blood glucose.
• Ganong's Review of Medical Physiology (26th ed.): "Deviations from a given normal set point are detected by a sensor, and signals from the sensor trigger compensatory changes that continue until the set point is again reached."

---

3. CONTROL CENTER (Integrating Center / Comparator)

• Receives the afferent signal from the receptor.
• Compares the current value with the reference value (set point).
• Determines the magnitude and direction of the needed response.
• Generates an error signal (difference between actual value and set point).
• Examples:
  • The hypothalamus: thermoregulatory center, osmolality control, hunger/satiety.
  • The medullary cardiovascular center: blood pressure regulation.
  • The respiratory center in the medulla: regulation of ventilation.
  • The hypothalamus-pituitary axis: hierarchical endocrine control (e.g., hypothalamus → anterior pituitary → adrenal cortex → cortisol → blood glucose).

---

4. EFFECTOR

• Receives the efferent signal from the control center and executes the corrective response.
• Can be muscle, gland, or organ.
• Produces a response that brings the controlled variable back to the set point.
• Examples:
  • Skeletal muscles shiver (thermogenesis) when body temperature falls.
  • Sweat glands increase secretion when body temperature rises.
  • Pancreatic beta cells secrete insulin in response to high blood glucose.
  • The kidney increases/decreases water reabsorption in response to ADH (regulating osmolality).
  • Arterioles vasoconstrict or vasodilate to regulate blood pressure.

---

5. FEEDBACK LOOP

A. Negative Feedback (most common, stabilizing)

• The response of the effector opposes (reverses) the original stimulus.
• Brings the variable back to the set point - stabilizes the system.
• Accounts for the vast majority of homeostatic mechanisms in the body.

1. Sensor - detects the parameter
2. Comparator - compares to the set point, generates a difference (error) signal
3. Gain - the error signal is multiplied by a proportionality factor
4. Effector - output activates an effector that opposes the deviation

• Blood glucose rises → Insulin secreted → Glucose uptake increases → Blood glucose falls back to set point.
• Blood pressure rises → Baroreceptors fire → Vagus nerve slows heart → BP falls.
• Core temperature rises → Sweating + vasodilation → Heat loss → Temperature returns to 37°C.

B. Positive Feedback (amplifying, destabilizing - used in special situations)

• The response reinforces the original stimulus - drives the variable further from the set point until a specific endpoint is reached.
• Used where a rapid, explosive, self-terminating response is needed.

• Parturition (childbirth): Uterine contractions push fetal head against cervix → more oxytocin released → stronger contractions → delivery (endpoint terminates the loop).
• Blood clotting (platelet aggregation): Platelet activation releases ADP → recruits more platelets → clot forms.
• Nerve action potential: Depolarization opens more Na+ channels → more depolarization → until reversal at +30 mV (inactivation terminates the cycle).
• LH surge at ovulation: Rising estrogen → positive feedback on pituitary → LH surge → ovulation.

---

HIERARCHY AND COMPLEXITY OF FEEDBACK LOOPS

• Synergistic loops: Insulin lowers blood glucose; glucagon raises it - opposing loops that together maintain glucose in a narrow range.
• Antagonistic loops: Epinephrine and cortisol both raise blood glucose; insulin opposes them.
• Hierarchy: Hypothalamus controls anterior pituitary → which controls adrenal cortex → which releases cortisol → which controls blood glucose.

• Medical Physiology (Boron & Boulpaep), Chapter 1

---

ORGAN SYSTEMS CONTRIBUTING TO HOMEOSTASIS

---

CLINICAL RELEVANCE

• Failure of glucose homeostasis → Diabetes mellitus
• Failure of blood pressure homeostasis → Hypertension / Shock
• Failure of pH homeostasis → Acidosis / Alkalosis
• Failure of temperature homeostasis → Fever / Hypothermia
• Failure of electrolyte homeostasis → Arrhythmias (K+/Ca2+), Seizures (Na+/Ca2+)

---

SUMMARY TABLE

---

• Medical Physiology, Boron & Boulpaep - Chapter 1: Foundations of Physiology
• Ganong's Review of Medical Physiology, 26th Ed. - Chapter 2: Functional Morphology and Homeostasis

---

Enzymes: Definition, Factors Affecting Activity, Michaelis-Menten Kinetics & Lineweaver-Burk Plot

---

I. DEFINITION OF AN ENZYME

• Enzymes act by forming an enzyme-substrate (ES) complex at the active site
• They lower the activation energy (Ea) of a reaction, dramatically increasing reaction rate
• They are highly specific (one enzyme, one substrate or class of substrates)
• They are not consumed - they are regenerated after each reaction cycle

E + S  ⇌  ES  →  E + P
       k₁  k₋₁   k₂

• Tietz Textbook of Laboratory Medicine, 7th Ed.

---

II. FACTORS AFFECTING ENZYME ACTIVITY

---

1. ENZYME CONCENTRATION

• When substrate is present in excess (saturating), the rate of reaction is directly proportional to enzyme concentration
• Adding more enzyme increases the concentration of the ES complex, and therefore increases the overall rate
• This is the basis for quantitative determination of enzymes in clinical labs (measuring reaction rates)

Reaction rate
     |         /
     |        /
     |       /
     |      /  (linear relationship)
     |     /
     |____/________________
              [Enzyme]

---

2. SUBSTRATE CONCENTRATION (and the Michaelis-Menten curve)

• At low [S]: reaction is first order - rate is proportional to [S] (only a fraction of enzyme is bound to substrate)
• At high [S]: reaction is zero order - rate is independent of [S] (all enzyme is saturated with substrate → maximum velocity = Vmax)
• The relationship produces a rectangular hyperbola

---

3. TEMPERATURE

• Reaction rate increases with rising temperature (Q₁₀ = 1.7 to 2.5 for most enzymes)
• However, at high temperatures, the enzyme undergoes thermal denaturation (irreversible loss of 3D structure)
• These opposing effects produce an optimal temperature (bell-shaped curve)
• For most human enzymes: optimal temperature ~37°C (body temperature)
• At 60-70°C: thermal inactivation becomes virtually instantaneous

• Curve a: Non-enzymatic reaction - continues to rise with temperature
• Curve b: Fraction of active enzyme - decreases at high temperatures (denaturation)
• Curve c: Enzyme-catalyzed reaction - bell-shaped, with clear temperature optimum

---

4. pH

• Enzyme activity shows marked pH dependence (bell-shaped curve with a pH optimum)
• pH affects:
  1. Ionization of amino acid side chains at the active site (e.g., His, Asp, Lys, Cys)
  2. Ionization of the substrate itself
  3. The 3D conformation of the enzyme - extreme pH causes irreversible denaturation

Enzyme
Activity
    |        /\
    |       /  \
    |      /    \
    |     /      \
    |____/________\____
         pH opt
              pH →

---

5. INHIBITORS

A. Competitive Inhibition

• Inhibitor structurally resembles the substrate and binds to the same active site
• Competes with substrate for active site binding
• Effect: Km increases (apparent); Vmax is unchanged (can be overcome by excess substrate)
• Reversible - increasing [S] overcomes inhibition

B. Noncompetitive Inhibition

• Inhibitor binds to a different site (allosteric site) on the enzyme - can bind to both free enzyme AND the ES complex
• Does not compete with substrate - binding is independent
• Effect: Vmax decreases; Km is unchanged
• Cannot be overcome by increasing substrate concentration

C. Irreversible Inhibition

• Inhibitor forms a covalent bond with the enzyme - enzyme is permanently inactivated
• Cannot be reversed by dilution or excess substrate
• Example: Organophosphate compounds (nerve agents, insecticides) irreversibly inhibit acetylcholinesterase; Lead irreversibly inhibits ferrochelatase (heme synthesis)

---

6. ACTIVATORS AND COFACTORS

• Many enzymes require metal ions (cofactors) for full activity:
  • Mg²⁺ (kinases, ATPases)
  • Zn²⁺ (carboxypeptidase, carbonic anhydrase)
  • Fe²⁺/Fe³⁺ (cytochrome oxidase, peroxidase)
  • Ca²⁺ (calmodulin-dependent enzymes)
  • Co²⁺, Cu²⁺, Mn²⁺
• Coenzymes (e.g., NAD⁺, FAD, Coenzyme A) act as co-substrates, accepting or donating chemical groups during catalysis

---

III. MICHAELIS-MENTEN CONSTANT (Km)

Derivation

Definition of Km

Significance of Km

1. Measure of enzyme-substrate affinity:
   • Low Km = high affinity (enzyme reaches half-maximal rate at a low substrate concentration)
   • High Km = low affinity (enzyme needs more substrate to reach half-maximal rate)
2. Comparison of isoenzymes: Isoenzymes (e.g., LDH isoforms) from different tissues typically differ in their Km values for the same substrate
3. Identification of the physiological substrate: For enzymes that can act on multiple substrates, the substrate with the lowest Km is most likely the physiological substrate
4. Comparing similar enzymes from different species or sources
5. Setting assay conditions: In clinical enzyme assays, substrate concentration is maintained at ≥ 10 × Km (achieves ~91% of Vmax) to ensure zero-order kinetics and accurate measurement
6. Clinical importance - Hexokinase vs. Glucokinase:
   • Hexokinase: Km for glucose ~0.1 mM (high affinity - saturated at normal blood glucose)
   • Glucokinase (liver/beta cells): Km for glucose ~5-10 mM (low affinity - acts as a glucose sensor, activity responds to post-meal glucose rises)
7. Km of ~10⁻⁵ to 10⁻³ mol/L for the majority of enzymes

---

IV. LINEWEAVER-BURK PLOT (Double-Reciprocal Plot)

Problem with the Michaelis-Menten hyperbola

The Lineweaver-Burk Transformation

Reading the Graph

Uses of the Lineweaver-Burk Plot

1. Accurate determination of Km and Vmax from experimental data
2. Distinguishing types of enzyme inhibition - the most important application

Lineweaver-Burk Plot in Enzyme Inhibition

Limitations of Lineweaver-Burk Plot

• Points at low [S] (high values of 1/[S]) are subject to greater experimental error and are visually over-weighted
• Distortion of error is greatest at the extremes where the line is extrapolated
• Modern practice uses nonlinear regression software (e.g., DynaFit, SigmaPlot) to fit kinetic data directly

---

SUMMARY TABLE

---

• Tietz Textbook of Laboratory Medicine, 7th Ed., Chapter 25: Enzyme Kinetics
• Lippincott's Illustrated Reviews: Biochemistry, 8th Ed., Chapter 5: Enzymes
• Henry's Clinical Diagnosis and Management by Laboratory Methods, Chapter 21: Enzyme Kinetics

---

Classification of Enzymes and Mechanism of Action

MBBS Biochemistry

---

PART I: DEFINITION

---

PART II: CLASSIFICATION OF ENZYMES

A. IUB / EC Nomenclature System

• Each enzyme has a systematic name (describes the reaction) and a trivial/practical name
• Each enzyme carries a unique EC number with 4 digits: EC a.b.c.d
  • 1st digit = Class (one of 6)
  • 2nd digit = Subclass
  • 3rd digit = Sub-subclass
  • 4th digit = Serial number within sub-subclass

• ATP + creatine → ADP + creatine phosphate

---

The Six Major Classes of Enzymes (IUB Classification)

---

CLASS 1: OXIDOREDUCTASES (EC 1.x.x.x)

---

CLASS 2: TRANSFERASES (EC 2.x.x.x)

---

CLASS 3: HYDROLASES (EC 3.x.x.x)

---

CLASS 4: LYASES (EC 4.x.x.x)

---

CLASS 5: ISOMERASES (EC 5.x.x.x)

---

CLASS 6: LIGASES (EC 6.x.x.x)

---

Summary Table - Six Classes of Enzymes

---

PART III: MECHANISM OF ACTION OF ENZYMES

A. The Active Site

1. The substrate binds (substrate-binding site)
2. Catalysis occurs (catalytic site)

---

B. How Enzymes Lower Activation Energy

• The transition state (T)* is the high-energy intermediate at the peak of the energy barrier
• Enzymes stabilize the transition state, increasing the number of molecules that can pass over the energy barrier
• Enzymes do not change the equilibrium of the reaction; they only speed up the rate at which equilibrium is reached
• Enzymes accelerate both the forward and reverse reactions equally

---

C. Substrate Binding Models

1. Lock-and-Key Model (Emil Fischer, 1894)

2. Induced-Fit Model (Daniel Koshland, 1958)

• Repositions functional groups in the active site optimally
• Increases binding affinity (more interactions form)
• Excludes water from the active site
• Properly aligns catalytic residues for bond-making/breaking

• Why substrates of slightly different structure may still bind (flexibility)
• Allosteric regulation (binding at one site changes the active site)
• Cooperativity in multimeric enzymes (binding one subunit induces conformational change in neighboring subunits)

---

D. Chemical Mechanisms of Catalysis at the Active Site

1. Acid-Base Catalysis (General Acid-Base Catalysis)

• Amino acid residues in the active site act as proton donors (general acids) or proton acceptors (general bases)
• Most commonly performed by Histidine (His) - because its pKa (~6.0) is close to physiological pH, allowing it to both donate and accept protons under cellular conditions
• Also performed by Asp, Glu, Lys, Tyr

2. Covalent Catalysis

• A nucleophilic group on the enzyme attacks the substrate, forming a transient covalent bond (covalent intermediate)
• The intermediate is subsequently resolved, releasing product and regenerating the free enzyme
• Amino acids involved: Serine (Ser), Cysteine (Cys), Lysine (Lys), Histidine (His), Aspartate (Asp)

• Chymotrypsin: Ser195 forms a covalent acyl-enzyme intermediate with the substrate
• Pyruvate decarboxylase: Thiamine pyrophosphate (cofactor) forms a covalent intermediate with pyruvate

3. Electrostatic Catalysis (Charge Stabilization)

• Charged amino acid side chains or metal ions in the active site stabilize charges that develop on the substrate during the transition state
• Lysine (Lys), Arginine (Arg) stabilize negative charges (e.g., phosphate groups)
• Aspartate (Asp), Glutamate (Glu) stabilize positive charges
• Metal ions (Zn²⁺, Mg²⁺, Fe²⁺) are particularly effective electrostatic catalysts

4. Transition State Stabilization

• The most important catalytic mechanism
• The active site has greater affinity for the transition state than for the substrate or product
• By binding the transition state tightly, the enzyme lowers its energy, reducing the energy barrier
• Transition state analogs (drugs that mimic the transition state) bind extremely tightly to enzymes (competitive inhibitors used as drugs - e.g., statins)

5. Proximity and Orientation Effects (Proximity Catalysis)

• The active site positions substrate molecules in the optimal geometry for reaction
• Reactants are brought into close proximity, greatly increasing the effective concentration
• This overcomes the entropy barrier (reduces randomness) - essentially making an intramolecular reaction out of an intermolecular one
• Estimated to accelerate reactions by factors of 10⁸ compared to the free solution reaction

6. Metal Ion Catalysis

• Metal cofactors (Mg²⁺, Zn²⁺, Fe²⁺/³⁺, Cu²⁺, Mn²⁺) contribute to catalysis by:
  • Acting as Lewis acids (electron pair acceptors) - activating substrates
  • Stabilizing transition states and reaction intermediates
  • Facilitating oxidation-reduction reactions (Fe, Cu - can change valence states)
  • Holding substrates in the correct orientation

• Carbonic anhydrase - Zn²⁺ activates water (carbonic anhydrase is ~10⁷ times faster than uncatalyzed reaction)
• Cytochrome oxidase - Fe²⁺/Fe³⁺ in heme group for electron transfer
• DNA polymerase - Mg²⁺ stabilizes the transition state during phosphodiester bond formation

---

E. Overall Sequence of Enzyme Catalysis

Step 1:  E + S  →  ES        (substrate binds at active site; induced fit occurs)
Step 2:  ES     →  ES*       (transition state is formed and stabilized)
Step 3:  ES*    →  EP        (bonds rearranged; product formed)
Step 4:  EP     →  E + P     (product is released; free enzyme regenerated)

---

F. Enzyme Specificity

---

SUMMARY

CLASSIFICATION OF ENZYMES (IUB/EC System)
├── Class 1: OXIDOREDUCTASES  → Redox reactions (LDH, ALT, G6PD)
├── Class 2: TRANSFERASES     → Group transfer (AST, hexokinase, CK)
├── Class 3: HYDROLASES       → Hydrolysis (trypsin, ALP, amylase, lipase)
├── Class 4: LYASES           → Non-hydrolytic bond cleavage (aldolase, carbonic anhydrase)
├── Class 5: ISOMERASES       → Intramolecular rearrangement (phosphoglucose isomerase)
└── Class 6: LIGASES          → Bond formation + ATP (DNA ligase, acetyl-CoA carboxylase)

MECHANISM OF ACTION
├── Active site: substrate binds, catalysis occurs
├── Energy: enzymes lower Ea; do not change ΔG or equilibrium
├── Substrate binding models:
│   ├── Lock-and-key (rigid complementarity)
│   └── Induced fit (flexible, conformational change on substrate binding) ← accepted model
└── Chemical mechanisms:
    ├── Acid-base catalysis (His, Asp, Lys)
    ├── Covalent catalysis (Ser, Cys - transient covalent intermediate)
    ├── Electrostatic catalysis (charged amino acids, metal ions)
    ├── Transition state stabilization (most important)
    ├── Proximity & orientation effects
    └── Metal ion catalysis (Zn²⁺, Mg²⁺, Fe²⁺)

---

• Tietz Textbook of Laboratory Medicine, 7th Ed. - Chapter 25: Enzymes
• Lippincott's Illustrated Reviews: Biochemistry, 8th Ed. - Chapter 5: Enzymes
• Henry's Clinical Diagnosis and Management by Laboratory Methods - Chapter 21
• Basic Medical Biochemistry: A Clinical Approach, 6th Ed. - Chapter 8

---

Isoenzymes: Definition, Identification Methods, and Clinical Importance of CK and LDH

---

PART I: WHAT ARE ISOENZYMES?

• All catalyze the same chemical reaction
• Have slightly different physical, chemical, and immunological properties
• Arise from genetically determined differences in amino acid sequence

• Lippincott's Illustrated Reviews: Biochemistry, 8th Ed.

Key Features of Isoenzymes

Origin of Isoenzymes

1. Multiple gene loci: Different structural genes encode different subunits (e.g., H and M subunits of LDH encoded on chromosomes 11 and 12)
2. Different combinations of subunits: Dimers or tetramers assembled from different subunit types (e.g., LDH has 5 isoenzymes from combinations of H and M subunits; CK has 3 from B and M subunits)
3. Post-translational modifications: Same protein but different carbohydrate additions (e.g., bone, liver, and intestinal ALP isoenzymes have identical amino acid sequences but differ in glycosylation)
4. Mitochondrial vs. cytoplasmic forms: Distinct isoenzymes encoded separately (e.g., mitochondrial and cytoplasmic CK, mitochondrial and cytoplasmic AST)

---

PART II: METHODS FOR IDENTIFICATION OF ISOENZYMES

---

1. ELECTROPHORESIS

• Support media: agarose gel or cellulose acetate at pH 8.6
• Sample (serum or tissue extract) is applied at the origin
• Electric current applied - isoenzymes migrate based on charge and size
• Visualization: substrate + NADPH-generating coupled reaction → fluorescence under UV light (360 nm)

• CK-1 (BB) → fastest (most negative charge)
• CK-2 (MB) → intermediate
• CK-3 (MM) → slowest (remains near origin)

---

2. IMMUNOASSAY (Immunochemical Methods)

• Immunoinhibition: An antibody against one subunit (e.g., anti-M antibody) inhibits that subunit's activity, leaving only the other subunit's activity to be measured
  • e.g., Anti-M antibody inhibits the M subunit of CK → only B subunit activity remains → this equals twice the CK-MB activity
• Sandwich immunoassay (mass assay): Two monoclonal antibodies (capture + detection) specifically recognize the MB dimer → measures CK-MB protein concentration (mass) in µg/L
  • Currently the recommended approach for CK-MB
  • More sensitive than activity assays (detection limit < 1 µg/L)
  • Not affected by hemolysis, anticoagulants, or inhibitors
  • Upper reference limit (URL): 5.0 µg/L for CK-MB

---

3. COLUMN CHROMATOGRAPHY (Ion-Exchange Chromatography)

---

4. HEAT STABILITY / HEAT INACTIVATION

• Heat-stable ALP - placental ALP (Regan isoenzyme) retains activity after heating to 56°C for 30 min
• Heat-labile ALP - bone ALP is inactivated at 56°C
• This forms the basis of the heat inactivation test to distinguish bone from liver ALP
• LDH-1 (cardiac) is heat-stable at 60°C; LDH-5 (liver/skeletal muscle) is heat-labile

---

5. CHEMICAL INHIBITION

• L-Phenylalanine: Inhibits intestinal and placental ALP but not liver/bone ALP
• Levamisole: Inhibits liver and bone ALP
• Urea inhibition: Used to differentiate bone from liver ALP isoenzymes
• These allow selective inhibition to identify which isoenzyme is elevated clinically

---

Additional Methods (Less Routine)

---

PART III: CLINICAL IMPORTANCE OF CK ISOENZYMES

Structure of Creatine Kinase (CK)

• EC number: 2.7.3.2 (Transferase - phosphate group transfer)
• Structure: Dimer (82 kDa), composed of two subunits:
  • B subunit (Brain type) - encoded on chromosome 14
  • M subunit (Muscle type) - encoded on chromosome 19
• Three isoenzymes result from combination of these two subunits:

Tissue Distribution of CK Isoenzymes

Normal Serum CK Activity

• CK-MM: ~96-100% of total serum CK (from physiological muscle turnover)
• CK-MB: ≤5% (very small amount may be normally present)
• CK-BB: none (does not normally cross the blood-brain barrier)

Clinical Uses of CK Isoenzymes

1. Acute Myocardial Infarction (AMI) - HISTORICAL SIGNIFICANCE

• CK-MB >5% of total CK = highly specific for myocardial damage
• Useful for estimating infarct size (peak CK-MB correlates with area of myocardium damaged)
• Useful for detecting reinfarction: if CK-MB falls and then rises again within 72h = reinfarction

• Cardiac troponins I and T (cTnI, cTnT) are now the gold standard - they are more sensitive, more specific, and remain elevated longer (3-10 days)
• CK-MB lacks specificity since it is also present in skeletal muscle (albeit < 5%)

2. Skeletal Muscle Disease

• Muscular dystrophies (e.g., Duchenne): Very high total CK (10-100× URL); predominantly CK-MM; CK-MB may be elevated due to "fetal reversion" (diseased muscle re-expresses B subunit)
• Polymyositis/Dermatomyositis: Elevated CK-MM ± CK-MB (due to fetal reversion)
• Rhabdomyolysis: Massive CK-MM elevation (>50× URL); risk of renal failure
• Statin myopathy: CK elevation graded from asymptomatic (< 4× URL) to rhabdomyolysis (> 50× URL)
• Note: CK-MB/total CK may be elevated in skeletal muscle disease WITHOUT MI - troponin levels (normal) differentiate the two

3. CK-BB (CK-1) - Brain/CNS

• Not normally present in blood (blood-brain barrier prevents entry)
• Elevated CK-BB in serum/CSF indicates brain damage:
  • Cerebral infarction (stroke)
  • Head trauma - CSF CK-BB correlates with severity
  • After cardiac arrest (global brain ischemia): CSF CK-BB peaks at ~48h
    • CK-BB < 5 U/L = minimal neurological damage
    • CK-BB 5-20 U/L = mild to moderate CNS injury
    • CK-BB 21-50 U/L = often fatal
    • CK-BB > 50 U/L = essentially 100% mortality
  • Subarachnoid hemorrhage: CK-BB > 40 U/L = 100% chance of unfavorable outcome

4. Macro-CK and Other Abnormal Forms

• Macro-CK type 1: CK-BB bound to immunoglobulins (most common) → falsely elevated CK-MB on immunoinhibition assays; detected by electrophoresis
• Macro-CK type 2: Mitochondrial CK oligomers released from severely damaged tissue (liver, heart) → poor prognosis marker
• Hypothyroidism: Average 5× increase in CK (predominantly CK-MM); normalizes with thyroid hormone replacement

---

PART IV: CLINICAL IMPORTANCE OF LDH ISOENZYMES

Structure of Lactate Dehydrogenase (LDH)

• EC number: 1.1.1.27 (Oxidoreductase)
• Reaction: L-Lactate + NAD⁺ ⇌ Pyruvate + NADH (reversible)
• Structure: Tetramer (4 subunits), composed of two types:
  • H subunit (Heart type) - encoded on chromosome 12
  • M subunit (Muscle type) - encoded on chromosome 11
• Five isoenzymes formed by combination of H and M subunits in a tetramer:

Normal Serum LDH Pattern

Clinical Uses of LDH Isoenzymes

1. Acute Myocardial Infarction (AMI) - HISTORICAL

• After AMI, LD1 rises above LD2 → called the "LD1/LD2 flip" (LD1 > LD2)
• LDH rises 12-24 hours after AMI, peaks at 48-72 hours, and remains elevated for 7-10 days
• This prolonged elevation made LDH useful for late presentation MI (when CK-MB had already normalized)
• Significance of LD flip: LD1 > LD2 pattern is highly specific for myocardial or red cell damage
• Now largely replaced by troponins (remain elevated 3-10 days and are more specific)

2. Liver Disease

• Viral hepatitis, cirrhosis, liver metastases: LD5 predominantly elevated
• LD5/LD4 ratio elevated in hepatic damage
• LDH is not liver-specific (also elevated in muscle), so elevated LD5 must be interpreted alongside ALT/AST

3. Megaloblastic Anemia / Hemolytic Anemia

• Massive elevation of total LDH with predominance of LD1 and LD2
• Due to destruction of RBCs (which are rich in LD1 and LD2)
• Very high LDH in megaloblastic anemia (ineffective erythropoiesis) and intravascular hemolysis
• Used in diagnosis of hemolytic anemia; also elevated in paroxysmal nocturnal hemoglobinuria (PNH)

4. Malignancy

• Total LDH is a non-specific tumor marker - elevated in many cancers
• LDH isoenzyme pattern in malignancy:
  • Leukemias/lymphomas: LD3 and LD4 elevated (lymphocyte-associated)
  • Lung cancer: LD3 elevated
  • Hepatic metastases: LD5 elevated
  • Leptomeningeal metastases (breast, lung, melanoma): CSF LD5/total LD ratio elevated above 10-15%
• LDH is a prognostic marker in testicular cancer, lymphoma, and melanoma staging (elevated LDH = worse prognosis)

5. Pulmonary Infarction (Pulmonary Embolism)

• Classic triad (historical): Elevated LDH, elevated bilirubin, normal AST - "Wacker triad"
• LD3 and LD4 elevated (lung-associated)
• Now largely replaced by CT pulmonary angiography and D-dimer testing

6. Renal Infarction

• LD1 elevated (kidney cortex is rich in LD1)

7. Meningitis

• Bacterial meningitis: CSF LDH elevated (> 40 U/L); sensitivity ~86%, specificity ~93%
• Bacterial > viral meningitis; can help differentiate
• Elevated CSF LD5 in CNS malignancy

CK-MB and Cardiac Troponin Timeline after AMI

---

SUMMARY TABLE: CK vs LDH Isoenzymes

---

SUMMARY

• Isoenzymes are multiple molecular forms of the same enzyme, differing in physical and chemical properties but catalyzing the same reaction
• They are identified by electrophoresis (separates all forms), immunoassay (most sensitive, recommended for CK-MB), heat stability, chemical inhibition, and chromatography
• CK-MB is specific for myocardial damage when > 5% of total CK; rises at 4-8h, peaks at 24h, normalizes at 48-72h post-MI
• LDH "flip" (LD1 > LD2) indicates myocardial/RBC damage; persists for up to 10 days
• Both have been superseded by cardiac troponins as the gold standard for MI diagnosis
• LDH isoenzymes remain clinically useful in hemolytic anemia, liver disease, malignancy, and meningitis

---

• Lippincott's Illustrated Reviews: Biochemistry, 8th Ed., Chapter 5
• Tietz Textbook of Laboratory Medicine, 7th Ed., Chapter 32
• Henry's Clinical Diagnosis and Management by Laboratory Methods, Chapter 21

---

GLYCOLYSIS

MBBS Biochemistry - Complete Answer

---

PART I: DEFINITION AND SALIENT FEATURES

Definition

Glucose + 2 ADP + 2 Pi + 2 NAD⁺ → 2 Pyruvate + 2 ATP + 2 NADH + 2 H₂O

Glucose + 2 ADP + 2 Pi → 2 Lactate + 2 ATP + 2 H₂O

---

SALIENT FEATURES OF GLYCOLYSIS

1. Location: Entirely cytoplasmic (cytosol) - all 10 enzymes are soluble in the cytoplasm. Does NOT require mitochondria.
2. Universal pathway: Present in ALL mammalian cells - obligatory in cells lacking mitochondria (RBCs, lens of eye, renal medulla, WBCs, platelets).
3. Anaerobic capacity: Can proceed without oxygen - the only source of ATP for anaerobically functioning tissues (RBCs, exercising muscle, retina, cornea).
4. Substrate: Primarily glucose, but also fructose and galactose (after conversion to glycolytic intermediates). Can also process glucose derived from glycogen (enters as glucose-6-phosphate after glycogenolysis, saving 1 ATP).
5. Two phases:
   • Preparatory/Investment phase (reactions 1-5): Consumes 2 ATP; glucose is phosphorylated twice and split into two triose phosphates.
   • Payoff/Energy-generating phase (reactions 6-10): Generates 4 ATP + 2 NADH per glucose (× 2 because of split); produces pyruvate.
6. Three irreversible steps (committed/regulatory steps):
   • Step 1: Hexokinase/Glucokinase (Glucose → Glucose-6-P)
   • Step 3: Phosphofructokinase-1 (Fructose-6-P → Fructose-1,6-bisP) ← rate-limiting step
   • Step 10: Pyruvate kinase (Phosphoenolpyruvate → Pyruvate)
7. Net ATP production: 2 ATP per glucose (4 produced - 2 consumed in investment phase)
8. Energy yield by substrate-level phosphorylation (not oxidative phosphorylation) in the glycolytic pathway itself.
9. Produces 2 NADH (from glyceraldehyde-3-phosphate dehydrogenase, step 6); these must be either:
   • Reoxidized in the mitochondria (aerobic: yields 5 ATP via malate-aspartate shuttle, or 3 ATP via glycerophosphate shuttle)
   • Or used to reduce pyruvate to lactate (anaerobic - regenerates NAD⁺)
10. Key feature - NAD⁺ recycling: Glycolysis requires a continuous supply of NAD⁺. Under aerobic conditions, NADH is reoxidized in the ETC. Under anaerobic conditions, NAD⁺ is regenerated by the lactate dehydrogenase reaction. Without this, glycolysis would halt.

---

PART II: THE TEN STEPS OF GLYCOLYSIS

PHASE I: PREPARATORY PHASE (ATP-consuming)

End of investment phase: 2 ATP consumed; 1 glucose → 2 × Glyceraldehyde-3-phosphate (G3P)

---

PHASE II: PAYOFF PHASE (ATP-generating) — ×2 because of split

Net from payoff phase: 4 ATP + 2 NADH per glucose

---

PART III: INHIBITORS OF GLYCOLYSIS

Key Points on Inhibitors

• Fluoride → used in grey-top blood glucose tubes (NaF) to prevent in vitro glycolysis by RBCs after blood collection
• Iodoacetate → classic experimental glycolysis inhibitor; blocks –SH group of G3P dehydrogenase
• Arsenate → a cunning inhibitor: allows glycolysis to proceed but uncouples ATP production (substrate-level phosphorylation) at step 6-7, resulting in no net ATP
• Tumor cells (Warburg effect) are particularly vulnerable to glycolysis inhibitors like 2-DG

---

PART IV: FATE OF PYRUVATE

                         PYRUVATE
                            │
          ┌─────────────────┼──────────────────┐────────────────┐
          ▼                 ▼                  ▼                ▼
    (Anaerobic)        (Aerobic)         (Gluconeogenesis)  (Amino acids)
       Lactate          Acetyl-CoA        Oxaloacetate        Alanine
          │            (→ TCA cycle)     (→ Glucose)       (Transamination)
       LDH rxn        PDH complex

---

1. Conversion to LACTATE (Anaerobic / Cytoplasm)

• Anaerobic conditions (absence of O₂) - e.g., vigorous exercise, ischemia
• Tissues lacking mitochondria: RBCs (always), renal medulla, retina
• Very high rates of glycolysis (even with O₂) - "aerobic glycolysis / Warburg effect" in tumors

• Regenerates NAD⁺ - allows glycolysis to continue
• Lactate is exported to liver and reconverted to glucose via Cori cycle (gluconeogenesis)
• Excess lactate accumulation → Lactic acidosis (pH < 7.35 with elevated blood lactate > 5 mmol/L)

---

2. Conversion to ACETYL-CoA (Aerobic / Mitochondria)

1. Thiamine pyrophosphate (TPP) - Vitamin B₁ - decarboxylates pyruvate
2. Lipoic acid - accepts acetyl group
3. Coenzyme A (CoA) - accepts acetyl group to form acetyl-CoA
4. FAD - reoxidizes dihydrolipoamide
5. NAD⁺ - final electron acceptor → NADH

• Arsenite, mercuric ions (react with lipoic acid –SH groups)
• Thiamine deficiency (Vitamin B₁ deficiency) → pyruvate/lactate accumulate → Wernicke's encephalopathy, beriberi
• NADH, Acetyl-CoA (product inhibition)

• TCA (Krebs) cycle → complete oxidation to CO₂ + H₂O + ATP
• Fatty acid synthesis (in cytoplasm after transport)

---

3. Conversion to OXALOACETATE / GLUCOSE (Gluconeogenesis / Mitochondria)

• Requires biotin (Vitamin B₇) as coenzyme and Acetyl-CoA as allosteric activator
• OAA → PEPCK → PEP → ultimately → Glucose (gluconeogenesis)
• Important in fasting state and in liver/kidney

---

4. Conversion to ALANINE (Transamination)

• Alanine exported from muscle → liver → reconverted to pyruvate → gluconeogenesis
• Alanine-glucose (Cahill) cycle - analogous to Cori cycle but for amino acid transport

---

5. Conversion to ETHANOL (in yeast only)

---

PART V: ENERGETICS OF GLYCOLYSIS

A. ATP Balance of Glycolysis (Glucose to Pyruvate)

B. Complete Energy Yield Under Aerobic Conditions

C. Anaerobic Glycolysis Energetics

D. Energy from Glycogen (vs. Free Glucose)

• When glucose from glycogen enters glycolysis (as G6P), step 1 is bypassed → saves 1 ATP
• Net ATP from glycogen: 3 ATP (anaerobic); 33 ATP (aerobic)

---

PART VI: REGULATION OF GLYCOLYSIS

A. Allosteric Regulation (Instantaneous)

1. Hexokinase (Step 1)

• When G6P accumulates (downstream pathway saturated), hexokinase is turned off
• Glucokinase (liver/β-cells) is NOT inhibited by G6P → acts as a glucose sensor; allows liver to continue trapping glucose even when G6P is high

2. Phosphofructokinase-1 (PFK-1) - Step 3 (RATE-LIMITING)

• 2 ADP ⇌ ATP + 5'-AMP (adenylate kinase reaction)
• When ATP falls even slightly, AMP rises disproportionately → relieves PFK-1 inhibition → glycolysis accelerated

• Made by the bifunctional enzyme PFK-2/FBPase-2 from fructose-6-phosphate
• Activates PFK-1 (stimulates glycolysis); Inhibits fructose-1,6-bisphosphatase (inhibits gluconeogenesis)
• Regulation by hormones:
  • Insulin (fed state): Activates PFK-2 → ↑ F2,6P → ↑ glycolysis
  • Glucagon/fasting: Activates PKA → phosphorylates PFK-2 → inhibits PFK-2, activates FBPase-2 → ↓ F2,6P → ↓ glycolysis, ↑ gluconeogenesis

3. Pyruvate Kinase (Step 10)

---

B. Covalent Modification (Minutes)

• Pyruvate kinase is phosphorylated and INACTIVATED by PKA (cAMP-dependent protein kinase) in response to glucagon (fasting) or epinephrine (stress)
• PFK-2 is phosphorylated by PKA → inactivated → ↓ F2,6P → ↓ PFK-1 activity → ↓ glycolysis
• Insulin activates phosphatases that dephosphorylate and activate pyruvate kinase and PFK-2

---

C. Induction/Repression of Enzyme Synthesis (Hours to Days)

---

D. Summary Regulation Diagram

GLUCOSE
   │
   ▼  Hexokinase ←[Inhibited by G6P]
Glucose-6-P
   │
   ▼  PFK-1 ←[KEY RATE-LIMITING STEP]
          INHIBITED by: ATP, Citrate, H⁺, Glucagon
          ACTIVATED by: AMP, Fructose-2,6-bisP (most potent), Fructose-6-P
Fructose-1,6-bisP
   │             ↓ [Feedforward activation of pyruvate kinase]
   │
   ▼×2  (two triose phosphates)
   │
   ▼  NADH generated (G3P dehydrogenase)
   │
   ▼  2 ATP generated (Phosphoglycerate kinase)
   │
   ▼  Enolase ←[Inhibited by Fluoride]
   │
   ▼  Pyruvate kinase ←[INHIBITED by ATP, Alanine, Glucagon/PKA phosphorylation]
                        [ACTIVATED by F1,6bisP, Insulin]
PYRUVATE

---

SUMMARY TABLE: Glycolysis at a Glance

---

• Harper's Illustrated Biochemistry, 32nd Ed. - Chapters 17 & 19
• Lippincott's Illustrated Reviews: Biochemistry, 8th Ed.
• Basic Medical Biochemistry: A Clinical Approach, 6th Ed.

---

THE KREBS CYCLE (Citric Acid Cycle / TCA Cycle)

MBBS Biochemistry - Complete Answer

---

INTRODUCTION & NAMES

• Tricarboxylic Acid (TCA) cycle - because three-carboxylate compounds (citrate, isocitrate) are key intermediates
• Citric acid cycle - citrate was the first compound identified in the cycle

---

PART I: LOCATION

• The soluble enzymes are in the mitochondrial matrix (free or loosely attached)
• Succinate dehydrogenase (step 6) is embedded in the inner mitochondrial membrane (also a component of Complex II of the ETC)
• The enzymes and coenzymes of the respiratory chain (which reoxidize the NADH and FADH₂ produced) are also in the inner mitochondrial membrane

• O₂ is required to reoxidize NADH and FADH₂ produced by the cycle
• The ETC and ATP synthase are embedded in the inner mitochondrial membrane
• The cycle is therefore strictly aerobic

---

PART II: REACTIONS OF THE KREBS CYCLE - STEP BY STEP

Entry Reaction: Pyruvate → Acetyl-CoA (Pyruvate Dehydrogenase Complex)

---

THE KREBS CYCLE DIAGRAM

---

THE 8 STEPS IN DETAIL

Note: The cycle uses 2C (acetyl-CoA) + 4C (oxaloacetate) → 6C → regenerates 4C. Per turn of cycle: 2 CO₂ released, 3 NADH + 1 FADH₂ + 1 GTP produced.

---

STEP 1: Oxaloacetate + Acetyl-CoA → Citrate

---

STEP 2: Citrate → Isocitrate (via cis-Aconitate)

---

STEP 3: Isocitrate → α-Ketoglutarate + CO₂

---

STEP 4: α-Ketoglutarate → Succinyl-CoA + CO₂

---

STEP 5: Succinyl-CoA → Succinate + GTP

---

STEP 6: Succinate → Fumarate

---

STEP 7: Fumarate → L-Malate

---

STEP 8: L-Malate → Oxaloacetate + NADH

---

SUMMARY TABLE OF 8 REACTIONS

---

NET EQUATION PER ACETYL-CoA:

Acetyl-CoA + 3 NAD⁺ + FAD + GDP + Pi + 2 H₂O → 2 CO₂ + 3 NADH + FADH₂ + GTP + CoA-SH

---

PART III: INHIBITORS OF THE KREBS CYCLE

Special Note - Fluoroacetate Poisoning ("Lethal Synthesis"):

---

PART IV: ENERGETICS OF THE KREBS CYCLE

A. Products Per Turn (Per 1 Acetyl-CoA = Per 2C entering)

B. ATP Yield Per Turn of the Cycle

C. Total ATP from 1 Glucose (Aerobic Complete Oxidation)

D. Efficiency

• Complete aerobic oxidation: ∼40% of free energy of glucose captured as ATP
• Compare with anaerobic glycolysis: only 2 ATP per glucose
• TCA cycle accounts for ~65% of total ATP produced from glucose oxidation

---

PART V: REGULATION OF THE KREBS CYCLE

Primary Regulation: Supply of NAD⁺ (Respiratory Control)

• TCA cycle is tightly coupled to the ETC via NADH and FADH₂
• When ATP demand is high → ADP accumulates → ETC and oxidative phosphorylation speed up → NAD⁺ regenerated → TCA cycle accelerates
• When ATP is plentiful → ADP falls → ETC slows → NADH accumulates → NAD⁺ is limiting → TCA cycle slows
• The ATP/ADP ratio and NADH/NAD⁺ ratio are the master regulators

Site 1: Citrate Synthase (Step 1)

Site 2: Isocitrate Dehydrogenase (Step 3) - RATE-LIMITING

• When energy is low (↑ADP, ↓NADH/NAD⁺): isocitrate DH activated → cycle accelerates
• When energy is high (↑ATP, ↑NADH): isocitrate DH inhibited → cycle slows

Site 3: α-Ketoglutarate Dehydrogenase Complex (Step 4)

• Regulated similarly to PDH complex (product inhibition by succinyl-CoA and NADH)

Role of Calcium (Ca²⁺) in TCA Regulation

• Ca²⁺ rises during muscle contraction
• Activates all three regulated enzymes: PDH complex, isocitrate DH, and α-KG DH complex
• Ensures TCA cycle speeds up when energy demand increases (muscle contraction)
• Provides coordinated increase in ATP production to match demand

Hormonal Regulation

---

PART VI: CLINICAL AND METABOLIC SIGNIFICANCE

1. Final Common Pathway

• Carbohydrates (via pyruvate → acetyl-CoA)
• Fats (fatty acids → acetyl-CoA; also propionate → succinyl-CoA)
• Amino acids (glucogenic → OAA, α-KG, succinyl-CoA, fumarate, malate; ketogenic → acetyl-CoA)

2. Anaplerotic Reactions (Refilling the cycle)

• Pyruvate carboxylase: Pyruvate + CO₂ → OAA (main anaplerotic reaction; requires biotin + ATP)
• Glutamate/glutamine → α-KG (via transamination or glutamate dehydrogenase)
• Propionyl-CoA → Succinyl-CoA (odd-chain fatty acids, Val, Ile)

3. Biosynthetic Functions (Cataplerosis)

4. Clinical Conditions

---

SUMMARY DIAGRAM

                    Glucose (glycolysis)
                         ↓
                     PYRUVATE
                         ↓ PDH complex (×2)  [Inhibited by arsenite, thiamine deficiency]
              ACETYL-CoA (2C) + CO₂ + NADH
                    ↓
   OAA (4C) + Acetyl-CoA → CITRATE (6C)  [Citrate synthase; inhibited by ATP, NADH]
                    ↓ Aconitase [inhibited by fluoroacetate]
               ISOCITRATE (6C)
                    ↓ Isocitrate DH + NAD⁺ [RATE-LIMITING; inhibited by ATP/NADH; activated by ADP/Ca²⁺]
              α-KETOGLUTARATE (5C) + CO₂ + NADH ← 1st CO₂
                    ↓ α-KG DH complex + NAD⁺ [inhibited by arsenite/NADH/succinyl-CoA; activated by Ca²⁺]
              SUCCINYL-CoA (4C) + CO₂ + NADH ← 2nd CO₂
                    ↓ Succinate thiokinase
              SUCCINATE (4C) + GTP ← [only substrate-level phosphorylation in TCA]
                    ↓ Succinate DH + FAD [inhibited by malonate; Complex II of ETC]
              FUMARATE (4C) + FADH₂
                    ↓ Fumarase + H₂O
              L-MALATE (4C)
                    ↓ Malate DH + NAD⁺
              OXALOACETATE (4C) + NADH → cycle repeats

PER TURN: 2 CO₂, 3 NADH, 1 FADH₂, 1 GTP → ~10 ATP
PER GLUCOSE (2 turns): 4 CO₂, 6 NADH, 2 FADH₂, 2 GTP → ~20 ATP from TCA

---

• Harper's Illustrated Biochemistry, 32nd Ed. - Chapter 16
• Basic Medical Biochemistry: A Clinical Approach, 6th Ed. - Chapter 23
• Lippincott's Illustrated Reviews: Biochemistry, 8th Ed.

---

GLUCONEOGENESIS

MBBS Biochemistry - Complete Answer

---

PART I: DEFINITION

• The term comes from Greek: glukos (sweet/glucose) + neos (new) + genesis (creation)
• It is essentially the reversal of glycolysis, but is NOT a simple reversal - it uses 4 unique bypass enzymes to overcome the 3 irreversible steps of glycolysis
• Gluconeogenesis is a predominately hepatic (liver-based), aerobic, and energy-consuming process

---

PART II: SIGNIFICANCE OF GLUCONEOGENESIS & THE CORI CYCLE

Why Gluconeogenesis is Necessary

---

THE CORI CYCLE (Lactic Acid Cycle)

        MUSCLE / RBC                           LIVER
    ┌─────────────────────┐           ┌─────────────────────┐
    │  Glucose            │           │      Glucose         │
    │     ↓ (glycolysis)  │  ←glucose─│         ↑            │
    │  Lactate            │──lactate→ │  Gluconeogenesis      │
    │  (+ 2 ATP)          │           │  (costs 6 ATP)        │
    └─────────────────────┘           └─────────────────────┘
              BLOOD (circulation)

1. Anaerobic tissues (RBCs, white fast-twitch muscle fibers) produce lactate during glycolysis - net gain of 2 ATP
2. Lactate enters the bloodstream and is transported to the liver (and kidney)
3. Liver converts lactate → pyruvate (via LDH) → glucose via gluconeogenesis - costs 6 ATP
4. Glucose re-enters circulation and is used again by muscle/RBCs

• Muscle makes 2 ATP per glucose consumed
• Liver spends 6 ATP to reconvert lactate back to glucose
• Net energetic cost of Cori cycle = 4 ATP (paid by liver via fatty acid oxidation)
• The cycle does NOT create new carbon - it recycles carbon; energy is transferred from liver to peripheral tissues

• Prevents lactic acidosis during intense exercise by clearing lactate
• Preserves glucose supply to obligate glycolytic tissues
• Abnormal Cori cycling contributes to lactic acidosis in liver failure, metformin toxicity, and sepsis

---

THE GLUCOSE-ALANINE CYCLE (Cahill Cycle)

     MUSCLE                                    LIVER
  Glucose → Pyruvate                    Alanine → Pyruvate
     + Amino group (from AA catabolism)       ↓
  Pyruvate + NH₂ → Alanine (via ALT)   Gluconeogenesis
  Alanine → blood → liver              → Glucose → blood → muscle

• Transfers nitrogen (amino groups) as well as carbon, from muscle to liver
• Liver deaminates alanine → pyruvate + NH₃ → urea (urea cycle)
• This is the main mechanism by which muscle amino acids contribute to gluconeogenesis during prolonged fasting
• The ATP for this glucose synthesis comes from fatty acid oxidation in the liver

---

Tissue Interrelationships During Fasting

---

PART III: SUBSTRATES AND PATHWAY

A. Major Gluconeogenic Substrates

1. The PDH reaction (pyruvate → acetyl-CoA) is irreversible
2. Acetyl-CoA enters the TCA cycle as a 2C unit, and the 2 carbons released as CO₂ balance exactly the 2C added - there is no net gain of oxaloacetate

---

B. THE GLUCONEOGENIC PATHWAY - THE 4 UNIQUE BYPASS ENZYMES

---

BYPASS 1: Pyruvate → Phosphoenolpyruvate (PEP)

Pyruvate Carboxylase Pyruvate + CO₂ + ATP → Oxaloacetate (OAA) + ADP + Pi

• Cofactor: Biotin (carboxyl group carrier), Mg²⁺
• Location: Mitochondrial matrix
• Allosteric activator: Acetyl-CoA (when acetyl-CoA is high, fatty acids are being oxidized, which signals gluconeogenesis is needed)
• Allosteric inhibitor: ADP

• Reduced to malate (by mitochondrial malate dehydrogenase, using NADH)
• Malate is transported out via the malate-aspartate shuttle
• Reoxidized to OAA in the cytosol (by cytosolic malate dehydrogenase, generating NADH)

Phosphoenolpyruvate Carboxykinase (PEPCK) OAA + GTP → PEP + CO₂ + GDP

• Cofactor: GTP (donated by TCA cycle succinate thiokinase in liver/kidney)
• Location: Cytosol (in humans; some PEPCK is mitochondrial)
• Induced by glucagon, glucocorticoids; repressed by insulin
• Net at bypass 1: 1 ATP + 1 GTP consumed per pyruvate → PEP

---

BYPASS 2: Fructose-1,6-bisphosphate → Fructose-6-phosphate

Fructose-1,6-bisphosphatase (FBPase-1) Fructose-1,6-bisphosphate + H₂O → Fructose-6-phosphate + Pi

• Location: Cytosol
• Activators: Citrate, ATP (high energy)
• Inhibitors: AMP, Fructose-2,6-bisphosphate (F2,6P) - the most potent inhibitor
• Present in: liver, kidney, skeletal muscle; absent from heart and smooth muscle
• The opposing enzyme PFK-1 is inactive because F2,6P levels are low (glucagon → PKA → phosphorylates PFK-2 → decreases F2,6P)

---

BYPASS 3: Glucose-6-phosphate → Glucose

Glucose-6-phosphatase (G6Pase) Glucose-6-phosphate + H₂O → Glucose + Pi

• Location: Endoplasmic reticulum (ER) membrane - glucose-6-phosphate must be transported into the ER lumen for hydrolysis
• Present in: liver and kidney cortex ONLY (explains why only liver and kidney can export glucose)
• Absent from muscle and brain - these tissues cannot release free glucose into the blood
• Clinical: Deficiency = Von Gierke's disease (GSD Type I) - hypoglycemia, lactic acidosis, hepatomegaly

---

C. COMPLETE GLUCONEOGENESIS PATHWAY (from 2 Pyruvate to 1 Glucose)

2 PYRUVATE (mitochondria)
    ↓ Pyruvate carboxylase (×2) [+2 ATP, +2 CO₂, biotin]
2 OXALOACETATE
    ↓ Malate DH (×2) [using 2 NADH mitochondria]
2 MALATE → transported out of mitochondria
    ↓ Malate DH (×2) in cytosol [generates 2 NADH cytosol]
2 OXALOACETATE (cytosol)
    ↓ PEPCK (×2) [+2 GTP, releases 2 CO₂]
2 PEP ←── BYPASS 1 COMPLETE
    ↓ Enolase (×2) [reverse - adds H₂O]
2 2-Phosphoglycerate
    ↓ Phosphoglycerate mutase (×2)
2 3-Phosphoglycerate
    ↓ Phosphoglycerate kinase (×2) [uses 2 ATP]
2 1,3-Bisphosphoglycerate
    ↓ G3P dehydrogenase (×2) [uses 2 NADH - provided from OAA→malate conversion above]
2 Glyceraldehyde-3-phosphate (G3P)
    ↓ Triose phosphate isomerase
1 G3P + 1 DHAP
    ↓ Aldolase (reverse - condensation)
FRUCTOSE-1,6-BISPHOSPHATE
    ↓ Fructose-1,6-bisphosphatase [+H₂O] ←── BYPASS 2 COMPLETE
FRUCTOSE-6-PHOSPHATE
    ↓ Phosphoglucose isomerase
GLUCOSE-6-PHOSPHATE
    ↓ Glucose-6-phosphatase [+H₂O] ←── BYPASS 3 COMPLETE
GLUCOSE

---

D. ENTRY OF GLYCEROL INTO GLUCONEOGENESIS

1. Glycerol + ATP → Glycerol-3-phosphate (glycerol kinase, in liver)
2. Glycerol-3-phosphate + NAD⁺ → DHAP + NADH (glycerol-3-phosphate dehydrogenase)
3. DHAP → Gluconeogenesis (bypasses the pyruvate carboxylase and PEPCK steps entirely)

---

PART IV: ENERGETICS OF GLUCONEOGENESIS

Net Equation (from 2 Pyruvate → 1 Glucose)

2 Pyruvate + 4 ATP + 2 GTP + 2 NADH + 6 H₂O → Glucose + 4 ADP + 2 GDP + 6 Pi + 2 NAD⁺

ATP Cost Breakdown

Comparison with Glycolysis

• Gluconeogenesis costs 6 ATP equivalents per glucose - it costs 3× more than glycolysis yields
• This extra energy comes from fatty acid oxidation (which provides abundant acetyl-CoA and ATP in the fasting state)
• This also explains why acetyl-CoA activates pyruvate carboxylase - when FA oxidation is high, ATP and acetyl-CoA are abundant, signaling that gluconeogenesis can be fueled

From Lactate (Net)

• 2 ATP (pyruvate carboxylase)
• 2 GTP (PEPCK)
• 2 ATP (phosphoglycerate kinase)
• Total = 6 ATP equivalents - same total, but 2 NADH are provided by lactate → pyruvate oxidation (LDH), so no external NADH needed

---

PART V: REGULATION OF GLUCONEOGENESIS

A. Allosteric Regulation (Instantaneous)

1. Pyruvate Carboxylase vs. Pyruvate Dehydrogenase

• Acetyl-CoA and NADH accumulate
• Acetyl-CoA activates pyruvate carboxylase → more OAA → more glucose
• Acetyl-CoA and NADH inhibit PDH → pyruvate not burned → goes to gluconeogenesis
• This reciprocal regulation is the key switch from carbohydrate catabolism to gluconeogenesis

2. FBPase-1 vs. PFK-1 (the most important regulatory point)

• Insulin → activates PFK-2 → ↑F2,6P → glycolysis ON, gluconeogenesis OFF
• Glucagon → PKA → phosphorylates PFK-2/FBPase-2 → FBPase-2 domain active → ↓F2,6P → gluconeogenesis ON, glycolysis OFF

3. Glucose-6-phosphatase vs. Glucokinase

---

B. Covalent Modification (Rapid - minutes)

• Glucagon → cAMP → PKA → phosphorylates and inactivates pyruvate kinase
• PEP is no longer converted to pyruvate
• PEP can now proceed backward through gluconeogenesis
• This prevents a futile cycle (PEP → pyruvate → OAA → PEP would waste ATP)

• Glucagon → PKA → phosphorylates PFK-2/FBPase-2 → FBPase-2 domain active → ↓F2,6P → PFK-1 inhibited + FBPase-1 activated → gluconeogenesis

---

C. Enzyme Induction and Repression (Slow - hours)

---

D. Hormonal Regulation Summary

---

E. Substrate Availability (Permissive Regulation)

• Fasting → ↑glucagon → ↑lipolysis → ↑glycerol (substrate) + ↑fatty acids → ↑acetyl-CoA → activates pyruvate carboxylase
• Exercise → ↑lactate from muscle → ↑substrate supply → drives gluconeogenesis
• High-protein meal → ↑amino acids in portal blood → glucagon-stimulated hepatic AA uptake → ↑gluconeogenesis

---

COMPLETE SUMMARY TABLE

---

• Harper's Illustrated Biochemistry, 32nd Ed. - Chapters 16, 19
• Basic Medical Biochemistry: A Clinical Approach, 6th Ed. - Chapters 23, 28
• Medical Physiology, Boron & Boulpaep - Chapter 58

---

TOPIC 1: GLYCOGEN METABOLISM

---

PART I: DEFINITIONS

Glycogenesis

Glycogenolysis

Structure of Glycogen

• Branched glucose polymer; glucose units linked by α-1,4-glycosidic bonds in linear chains
• α-1,6 branches every 8-10 residues
• Reducing end attached to protein glycogenin
• All free ends = non-reducing ends (sites of synthesis and degradation)
• MW: 10⁷ to 10⁸ Da
• Liver glycogen: ~100-120 g (up to ~8% liver weight); depleted in ~24h fast
• Muscle glycogen: ~300-400 g total; used locally (muscle lacks glucose-6-phosphatase, so cannot export glucose)

---

PART II: GLYCOGENESIS - DETAILED PATHWAY

Steps of Glycogen Synthesis

Step 1: Glucose → Glucose-6-phosphate

Hexokinase (muscle) / Glucokinase (liver) Glucose + ATP → Glucose-6-phosphate + ADP Cost: 1 ATP

Step 2: Glucose-6-phosphate → Glucose-1-phosphate

Phosphoglucomutase G6P ⇌ G1P (reversible; Mg²⁺ required) Intermediate: Glucose-1,6-bisphosphate

Step 3: Glucose-1-phosphate → UDP-Glucose (Activation step)

UDP-glucose pyrophosphorylase (UTP:glucose-1-phosphate uridylyltransferase) G1P + UTP → UDP-Glucose + PPi PPi is immediately hydrolyzed by pyrophosphatase → 2 Pi (making reaction irreversible) Cost: 1 UTP (equivalent to 1 ATP) UDP-glucose is the "activated glucose" - the immediate donor for glycogen synthesis

Step 4: Elongation of Glycogen Chain

Glycogen Synthase (RATE-LIMITING, REGULATED enzyme) UDP-Glucose + glycogen (n residues) → Glycogen (n+1 residues) + UDP

• Transfers glucose from UDP-Glucose to the 4'-OH of the non-reducing end
• Forms α-1,4-glycosidic bond
• Requires a primer - cannot start a chain de novo

• Glycogenin is a self-glycosylating protein that forms the primer
• Adds glucose from UDP-glucose to its own Tyr194 residue (autoglycosylation)
• Extends the chain to ~8 residues → sufficient for glycogen synthase to act

Step 5: Branching

Branching enzyme (Amylo-4:6-transferase / α-1,4:α-1,6-glucan transferase)

• When the chain reaches ~11 residues, branching enzyme cleaves a 6-8 residue piece from the non-reducing end
• Reattaches it via an α-1,6 bond to an internal glucose (at least 4 residues from an existing branch)
• Creates a new non-reducing end → more sites for glycogen synthase
• Branching increases solubility and the rate of synthesis/degradation

Glycogenesis Diagram

Energy Cost of Glycogenesis

• Per glucose added to glycogen: 2 ATP equivalents (1 ATP for hexokinase + 1 UTP for UDP-glucose pyrophosphorylase; 2 Pi released from PPi hydrolysis)

---

PART III: GLYCOGENOLYSIS - DETAILED PATHWAY

Steps of Glycogen Degradation

Step 1: Shortening of Linear Chains

Glycogen Phosphorylase (RATE-LIMITING, REGULATED enzyme) Glycogen (n) + Pi → Glucose-1-phosphate + Glycogen (n-1)

• Phosphorolysis - uses Pi (not H₂O), so produces G1P directly (already phosphorylated → saves 1 ATP)
• Works from non-reducing ends toward branch points
• Cleaves α-1,4 bonds only
• Stops 4 residues before a branch point (cannot pass the α-1,6 link)
• Cofactor: Pyridoxal-5'-phosphate (PLP/vitamin B₆) - covalently bound
• Liver isoform = PYGL gene; Muscle isoform = PYGM gene

Step 2: Debranching (two activities of ONE enzyme)

• Transfers 3 of the 4 remaining residues to the non-reducing end of another chain via α-1,4 bond
• One glucose remains at the branch point linked by α-1,6

• Hydrolyzes the α-1,6 branch link
• Releases free glucose (not glucose-1-phosphate) - this is the only step producing free glucose

Glycogenolysis Diagram

Step 3: Glucose-1-phosphate → Glucose-6-phosphate

Phosphoglucomutase (same as in synthesis, but reverse direction) G1P → G6P

Step 4: G6P → Glucose (LIVER ONLY)

Glucose-6-phosphatase (ER membrane, liver and kidney only) G6P + H₂O → Glucose + Pi

• Glucose enters bloodstream to maintain blood glucose
• Muscle lacks G6P-ase → G6P enters glycolysis directly, cannot export glucose

Energetics of Glycogenolysis

• Per glucose released as G1P: 0 ATP consumed (phosphorolysis saves the 1 ATP cost of hexokinase)
• In glycolysis: G6P enters at step 1, already phosphorylated → net 3 ATP per glucose from glycogen (vs 2 ATP per free glucose in anaerobic glycolysis)

---

PART IV: REGULATION OF GLYCOGEN METABOLISM

• Glycogen synthase (synthesis): active when dephosphorylated (form a/I); inactive when phosphorylated (form b/D)
• Glycogen phosphorylase (degradation): active when phosphorylated (form a); inactive when dephosphorylated (form b)

1. Hormonal (covalent modification - rapid)
2. Allosteric (instantaneous)
3. Enzyme induction/repression (slow)

---

A. Regulation by Glucagon/Epinephrine (FASTING/STRESS)

Regulation Diagram

Glucagon/Epinephrine → GPCR → Adenylate cyclase → ↑cAMP
         ↓
    Protein Kinase A (PKA) - activated
         ↓
    Phosphorylase kinase - phosphorylated (inactive → active)
         ↓
    Glycogen phosphorylase b (inactive) → a (active) [phosphorylated at Ser14]
         ↓
    GLYCOGENOLYSIS ACTIVATED

PKA also:
    Glycogen synthase a (active) → b (inactive) [phosphorylated → OFF]
         ↓
    GLYCOGENESIS INHIBITED

---

B. Regulation by Insulin (FED STATE)

• Insulin → activates protein phosphatase 1 (PP1)
• PP1 dephosphorylates glycogen phosphorylase a → inactive phosphorylase b
• PP1 dephosphorylates glycogen synthase b → active glycogen synthase a
• Net: glycogenesis ON, glycogenolysis OFF
• Insulin also activates glucokinase (more G6P available → more UDP-glucose)

---

C. Allosteric Regulation (Instantaneous)

Glycogen Phosphorylase (Muscle - AMP Activation)

• In muscle, AMP accumulation during intense exercise directly activates glycogenolysis even without hormonal signal
• AMP activates phosphorylase b → promotes T-state → R-state conversion (active)

Glycogen Synthase

• After a meal: ↑blood glucose → ↑G6P (liver) → allosterically activates glycogen synthase → glycogen synthesis despite phosphorylation

---

D. Ca²⁺ Regulation (Exercise/Muscle Contraction)

• During muscle contraction: ↑cytosolic Ca²⁺
• Ca²⁺ binds calmodulin subunit of phosphorylase kinase
• Activates phosphorylase kinase even without phosphorylation by PKA
• Rapidly activates glycogen phosphorylase → glucose for contracting muscle
• Coordinates glycogenolysis with muscle contraction (both triggered by same Ca²⁺ signal)

---

E. Summary Regulation Table

---

Glycogen Storage Diseases (Key examples)

---

---

TOPIC 2: HMP PATHWAY (HEXOSE MONOPHOSPHATE SHUNT / PENTOSE PHOSPHATE PATHWAY)

---

PART I: OVERVIEW AND DEFINITION

1. Generates NADPH (primary reducing agent for biosynthesis and antioxidant defense)
2. Produces ribose-5-phosphate (essential for nucleotide/nucleic acid synthesis)
3. Does NOT produce or consume ATP directly
4. Serves as a link between the glucose pool and the pentose phosphate pool

• Oxidative phase (irreversible) - produces NADPH and ribulose-5-phosphate
• Non-oxidative phase (reversible) - interconverts sugar phosphates; can produce ribose-5-phosphate or return carbons to glycolysis

---

PART II: OXIDATIVE PHASE (IRREVERSIBLE)

Reaction 1: Glucose-6-phosphate → 6-Phosphogluconolactone

Enzyme: Glucose-6-phosphate dehydrogenase (G6PD) G6P + NADP⁺ → 6-Phosphogluconolactone + NADPH + H⁺

• RATE-LIMITING, REGULATED step (committed step)
• Cofactor: NADP⁺ (not NAD⁺ - this is key)
• Inhibited by: NADPH (product inhibition - NADPH/NADP⁺ ratio controls flux)
• Activated by: ↑NADP⁺ (when NADPH is being consumed)
• Induced by: Insulin (in fed state)
• G6PD is X-linked; deficiency is the most common enzymopathy (G6PD deficiency)
• Produces first NADPH

Reaction 2: 6-Phosphogluconolactone → 6-Phosphogluconate

Enzyme: 6-Phosphogluconolactonase (Lactonase) 6-Phosphogluconolactone + H₂O → 6-Phosphogluconate

• Simple hydrolysis; spontaneous but enzyme-accelerated
• No cofactor, no energy change

Reaction 3: 6-Phosphogluconate → Ribulose-5-phosphate + CO₂

Enzyme: 6-Phosphogluconate dehydrogenase 6-Phosphogluconate + NADP⁺ → Ribulose-5-phosphate + CO₂ + NADPH + H⁺

• Oxidative decarboxylation (removes C1 as CO₂)
• Produces second NADPH
• Also irreversible
• Product: Ribulose-5-phosphate (a pentose phosphate)

Net of Oxidative Phase (per G6P):

G6P + 2 NADP⁺ + H₂O → Ribulose-5-P + CO₂ + 2 NADPH + 2H⁺

---

PART III: NON-OXIDATIVE PHASE (REVERSIBLE)

Initial Isomerizations:

Ribulose-5-phosphate isomerase: Ribulose-5-P → Ribose-5-phosphate (R5P) - used for nucleotide synthesis

Ribulose-5-phosphate 3-epimerase (Phosphopentose epimerase): Ribulose-5-P → Xylulose-5-phosphate (Xu5P)

The Interconversion Reactions:

Transketolase (transfers 2-carbon "ketol" unit; requires Thiamine Pyrophosphate/TPP)

Xylulose-5-P (5C) + Ribose-5-P (5C) → Sedoheptulose-7-P (7C) + Glyceraldehyde-3-P (3C)

Transaldolase (transfers 3-carbon unit; no cofactor needed)

Sedoheptulose-7-P (7C) + Glyceraldehyde-3-P (3C) → Fructose-6-P (6C) + Erythrose-4-P (4C)

Transketolase (second reaction)

Xylulose-5-P (5C) + Erythrose-4-P (4C) → Fructose-6-P (6C) + Glyceraldehyde-3-P (3C)

---

THE COMPLETE HMP PATHWAY DIAGRAM

---

Balanced Equations for Non-Oxidative Phase

6 Ribulose-5-P → 5 Glucose-6-P (via 5 G6P regenerated)

5 G6P → 6 Ribose-5-P (without going through oxidative phase; no NADPH generated)

---

PART IV: REGULATION OF THE HMP PATHWAY

Primary Regulation: NADPH/NADP⁺ Ratio

• This is the most important regulatory mechanism - a simple push-pull on G6PD
• The pathway is demand-driven by NADPH consumption

Secondary Regulation

Transketolase Regulation

• Transketolase requires Thiamine Pyrophosphate (TPP, vitamin B₁) as cofactor
• Thiamine deficiency → impairs non-oxidative phase → ribose-5-phosphate cannot be interconverted to glycolytic intermediates
• Red blood cell transketolase activation test: used to diagnose thiamine deficiency

---

PART V: SIGNIFICANCE OF THE HMP SHUNT

1. NADPH Production (Most Important)

2. Ribose-5-Phosphate Production

• Essential precursor for purine and pyrimidine nucleotide synthesis (ATP, GTP, NAD⁺, FAD, CoA)
• Required for DNA and RNA synthesis (proliferating cells)
• Active in: rapidly dividing cells, liver, bone marrow

3. Interconversion of Sugars

• Non-oxidative phase provides flexibility: pentose ↔ hexose ↔ triose
• Allows fructose-6-P and G3P to be produced from ribose-5-P when biosynthesis exceeds need
• Links HMP to glycolysis

4. G6PD Deficiency - Clinical Significance

• X-linked recessive; affects ~400 million people worldwide
• Most common in malaria-endemic regions (heterozygotes have relative protection against P. falciparum)

Oxidative stress (drugs, infection, fava beans, naphthalene)
    ↓
↑H₂O₂ and reactive oxygen species (ROS)
    ↓ Normal: NADPH → GSH → neutralizes H₂O₂
    ↓ In G6PD deficiency: No NADPH → GSH depleted
    ↓
Oxidation of hemoglobin → Heinz bodies (precipitated Hb)
    ↓
Rigid RBCs → splenic trapping → HEMOLYSIS
    ↓
Hemolytic anemia, jaundice, dark urine (hemoglobinuria)

5. NADPH Oxidase in Phagocytes (Respiratory Burst)

• Phagocytes use NADPH oxidase to generate superoxide (O₂⁻) → kills bacteria
• 2 NADPH + 2 O₂ → 2 NADP⁺ + 2 O₂⁻
• O₂⁻ → H₂O₂ → HOCl (bleach, via myeloperoxidase) → bactericidal
• Chronic Granulomatous Disease (CGD): NADPH oxidase deficiency → recurrent bacterial/fungal infections

---

COMBINED SUMMARY TABLES

Glycogen Metabolism Summary

HMP Shunt Summary

---

• Basic Medical Biochemistry: A Clinical Approach, 6th Ed. - Chapters 26, 29
• Lippincott's Illustrated Reviews: Biochemistry, 8th Ed. - Chapter 13
• Harper's Illustrated Biochemistry, 32nd Ed. - Chapter 18

---

VITAMINS A, C, AND D

MBBS Biochemistry - Complete Answer

---

═══════════════════════════════

VITAMIN A (RETINOL)

═══════════════════════════════

I. FORMS OF VITAMIN A

---

II. SOURCES

---

III. ABSORPTION AND TRANSPORT

A. Intestinal Absorption

1. Retinyl esters in food are hydrolyzed by retinyl ester hydrolase (pancreatic and brush border) → free retinol + FA
2. β-Carotene from plants is cleaved in the enterocyte by β-carotene 15,15'-dioxygenase → 2 molecules of retinal
3. Retinal is reduced to retinol in the enterocyte by retinaldehyde reductase (NADPH-dependent)
4. Retinol in the enterocyte is re-esterified with long-chain FA (primarily palmitate) by LRAT
5. Retinyl esters are packaged into chylomicrons and secreted into lymph (thoracic duct → blood)

B. Hepatic Storage

• Chylomicron remnants (containing retinyl esters) are taken up by liver
• Stored in hepatic stellate cells (Ito cells) as retinyl esters
• Liver is the main storage organ; ~90% of body's vitamin A is in the liver

C. Release and Blood Transport

• Retinol is released from the liver bound to Retinol-Binding Protein (RBP)
• RBP complexes with transthyretin (TTR/prealbumin) to form a ternary complex (Retinol-RBP-TTR)
• TTR prevents filtration by the kidney (RBP alone is too small)
• At target cells: complex binds to membrane receptor → retinol enters cell
• Inside cell: Intracellular Retinol-Binding Protein (CRBP) carries retinol to nucleus

D. Retinoic Acid Mechanism (Genomic Action)

• Retinol → oxidized to retinoic acid inside target cells
• Retinoic acid binds Retinoic Acid Receptors (RARs) in the nucleus
• RAR-retinoic acid complex binds Retinoic Acid Response Elements (RAREs) on DNA
• Regulates transcription → controls synthesis of specific proteins (e.g., keratin, growth factors)
• Acts like a steroid hormone (nuclear receptor superfamily)

---

IV. WALD'S VISUAL CYCLE (The Visual Cycle)

Components of Rhodopsin

• Opsin: a G protein-coupled receptor (7 transmembrane helices); protein component
• 11-cis Retinal: the chromophore (light-absorbing molecule); prosthetic group
• Together they form Rhodopsin (visual purple) in rod cells

The Cycle:

                          LIGHT
                            ↓
RHODOPSIN         11-cis retinal + Opsin
(dark adapted)    photoisomerization
                            ↓
                     All-trans retinal + Opsin
                     (BLEACHING - rhodopsin dissociates)
                            ↓
                     Activates G-protein TRANSDUCIN (Gt)
                            ↓
                     Phosphodiesterase activated → ↓cGMP
                            ↓
                     cGMP-gated Na⁺ channels CLOSE
                            ↓
                     HYPERPOLARIZATION of rod cell
                            ↓
                     Nerve impulse → optic nerve → brain
                     (perception of image)

REGENERATION OF RHODOPSIN:
All-trans retinal
     ↓ Retinal reductase + NADPH
All-trans retinol (transported to RPE - Retinal Pigment Epithelium)
     ↓ Retinyl ester formed (LRAT)
All-trans retinyl ester
     ↓ Isomerase (RPE65 - Retinal Pigment Epithelium enzyme)
11-cis retinol
     ↓ 11-cis retinol dehydrogenase + NAD⁺
11-cis retinal
     ↓ returns to rod cell, recombines with opsin
RHODOPSIN (regenerated - dark adaptation)

• Light triggers 11-cis → all-trans isomerization at the C11-C12 double bond
• All-trans retinal dissociates from opsin → "bleaches" the retina
• Regeneration requires RPE (retinal pigment epithelium) and vitamin A
• In night blindness (vitamin A deficiency): insufficient 11-cis retinal → rhodopsin cannot be regenerated → cannot adapt to dim light
• Cone cells use similar cycle with different opsins and color-specific pigments (photopsins)

---

V. RDA (Recommended Dietary Allowance)

• 1 RAE = 1 μg retinol = 12 μg β-carotene = 24 μg other carotenoids
• Tolerable Upper Intake Level (UL): 3,000 μg RAE/day for adults

---

VI. DEFICIENCY

Sequence of Deficiency Signs:

1. Loss of sensitivity to green light (earliest biochemical sign)
2. Night blindness (Nyctalopia) - inability to see in dim light; visual threshold elevated
3. Xerophthalmia - dryness of conjunctiva and cornea due to keratinization
4. Bitot's spots - triangular grey-white foamy deposits on bulbar conjunctiva (keratinized epithelium)
5. Corneal ulceration (keratomalacia) - severe stage; cornea softens and ulcerates
6. Corneal scarring and blindness (irreversible)

Other Deficiency Effects:

---

VII. TOXICITY (Hypervitaminosis A)

• Nausea, vomiting
• Headache (↑intracranial pressure)
• Blurred vision
• Skin desquamation

---

---

═══════════════════════════════

VITAMIN C (ASCORBIC ACID)

═══════════════════════════════

I. FORMS OF VITAMIN C

---

II. SOURCES

---

III. ABSORPTION AND TRANSPORT

• Absorbed in the small intestine (primarily duodenum and jejunum) via sodium-dependent active transport (SVCT1 - Sodium-Vitamin C Co-Transporter)
• At doses < 100 mg: ~almost 100% absorbed
• At doses > 1 g: only ≤ 50% absorbed (saturable transporter - absorption efficiency decreases at high doses)
• Excess: excreted in urine (vitamin C is not stored in large amounts)
• Blood transport: as free ascorbate in plasma
• Intracellular accumulation via SVCT2 (different isoform); WBCs and adrenal glands have highest concentrations

• Increased requirements: smoking, pregnancy, lactation, infection, trauma, hemodialysis
• Reduced absorption: malabsorption syndromes, alcoholism

---

IV. RDA

• Tolerable Upper Level (UL): 2,000 mg/day
• Minimum needed to prevent scurvy: ~10 mg/day
• Body pool: ~1,500 mg; clinical scurvy appears when pool falls below ~300 mg

---

V. FUNCTIONS

1. Collagen Synthesis (Most Important)

• Vitamin C is a coenzyme for prolyl hydroxylase and lysyl hydroxylase
• These enzymes hydroxylate proline → hydroxyproline and lysine → hydroxylysine within procollagen chains
• Hydroxyproline and hydroxylysine are essential for cross-linking of collagen triple helices → stable collagen
• Mechanism: Vitamin C keeps the iron cofactor of prolyl/lysyl hydroxylase in the reduced Fe²⁺ state (prevents oxidation to Fe³⁺, which inactivates the enzyme)
• In deficiency: collagen is unstable → cannot maintain connective tissue integrity → scurvy

2. Antioxidant Function

• Vitamin C is a direct free-radical scavenger
• Donates electrons to quench reactive oxygen species (ROS), superoxide, hydroxyl radical
• Regenerates Vitamin E from tocopheryl radical → synergistic antioxidant system
• Protects LDL from oxidation, cellular membranes, DNA

3. Iron Absorption Enhancement

• Reduces dietary non-heme iron (Fe³⁺ → Fe²⁺) in the intestine
• Fe²⁺ is more soluble and better absorbed via DMT-1 transporter
• Takes at the same time as iron-rich foods → significantly increases iron absorption
• Clinical use: give vitamin C with iron supplements in iron-deficiency anemia

4. Carnitine Biosynthesis

• Required for hydroxylation steps in carnitine synthesis
• Carnitine transports long-chain fatty acids into mitochondria for β-oxidation
• Vitamin C deficiency → ↓carnitine → ↓fatty acid oxidation → fatigue

5. Catecholamine Synthesis

• Dopamine β-hydroxylase requires vitamin C: converts dopamine → norepinephrine (in adrenal medulla)
• Adrenal glands have the highest concentration of vitamin C in the body

6. Tyrosine Catabolism

• Required for activity of 4-hydroxyphenylpyruvate dioxygenase → tyrosine degradation
• Deficiency → tyrosinemia of newborn

7. Drug and Steroid Metabolism

• Component of mixed-function oxidase systems (cytochrome P450) in liver microsomes
• Required for some xenobiotic hydroxylations

8. Immune Function

• Stimulates neutrophil and lymphocyte function
• Promotes production of interferon
• May reduce duration of common cold symptoms (mild effect)

9. Anti-Cancer (Emerging)

• High-dose IV ascorbic acid: pro-oxidant effect selectively toxic to cancer cells
• May work synergistically with gemcitabine, PD-1 inhibitors, radiation

---

VI. DEFICIENCY - SCURVY

Clinical Features (all due to defective collagen):

---

VII. TOXICITY

• Generally considered safe at usual dietary levels
• Doses > 2 g/day → abdominal pain, diarrhea, nausea (osmotic diarrhea - "bowel tolerance")
• Oxalate kidney stones: Vitamin C → metabolized to oxalate → risk of calcium oxalate stones in predisposed patients (especially those with renal disease or prior kidney stones)
• Iron overload: Theoretical risk of promoting iron absorption to excess in hereditary hemochromatosis
• Rebound scurvy: Abrupt cessation of high-dose supplements → may precipitate scurvy
• Interference with lab tests: High doses may give false-positive glucose (Clinitest) or interfere with stool occult blood tests (Hemoccult)

---

---

═══════════════════════════════

VITAMIN D (CALCIFEROL)

═══════════════════════════════

I. FORMS OF VITAMIN D

---

II. SOURCES

Endogenous Synthesis (Major Source in most humans)

• 7-Dehydrocholesterol (intermediate of cholesterol synthesis, accumulates in dermis/epidermis) is converted by UV-B light (280-315 nm) to Previtamin D₃ → thermally isomerizes to Cholecalciferol (D₃)
• Absorbed into bloodstream bound to Vitamin D-Binding Protein (DBP)
• In temperate climates: plasma vitamin D peaks at end of summer, lowest at end of winter
• Beyond latitude 40°N or 40°S: insufficient UV-B in winter for adequate synthesis

Dietary Sources

---

III. ACTIVATION (Wald's Cycle equivalent = VITAMIN D METABOLISM/HYDROXYLATION)

Two-Step Activation Pathway:

Step-by-Step:

• Relatively unregulated step
• This is the major circulating/storage form (measured for vitamin D status in blood; normal: 50-125 nmol/L or 20-50 ng/mL)
• Bound to vitamin D-binding protein (DBP) in plasma

• Tightly regulated (key control point)
• OR: 25-OH-D₃ → 24,25-(OH)₂-D₃ (inactive; degradation) by 24-hydroxylase (CYP24A1)

Regulation of 1α-Hydroxylase:

---

IV. RDA

• Deficient: < 50 nmol/L (< 20 ng/mL)
• Insufficient: 50-75 nmol/L
• Sufficient: > 75 nmol/L (> 30 ng/mL)
• Toxic: > 375 nmol/L (> 150 ng/mL)

---

V. FUNCTIONS

1. Calcium Homeostasis (Primary Function)

• Calcitriol enters intestinal enterocyte → binds nuclear Vitamin D Receptor (VDR)
• VDR-calcitriol complex → binds VDRE on DNA → induces transcription of:
  • Calbindin D (calcium-binding protein) - major calcium transport protein
  • TRPV6 (apical calcium channel)
  • PMCA1b (basolateral calcium pump)
• Net: ↑active Ca²⁺ absorption from duodenum and jejunum (up to 30-40% of intake vs 10-15% without vitamin D)

• Calcitriol induces calbindin D₂₈k in distal tubule → ↑ calcium reabsorption
• Works synergistically with PTH

• Calcitriol acts on osteoblasts → induces RANKL → activates osteoclasts
• Osteoclasts resorb bone → release Ca²⁺ and PO₄³⁻ into blood
• (Paradoxically, vitamin D is needed for bone formation; it ensures adequate serum Ca²⁺ for mineralization)

2. Phosphate Homeostasis

• Increases intestinal phosphate absorption (via sodium-phosphate cotransporter Npt2b)
• Increases renal phosphate reabsorption

3. Gene Regulation and Cell Differentiation

• VDR is a nuclear receptor found in >30 tissues
• Calcitriol regulates >1,000 genes
• Anti-proliferative / pro-differentiation effects in many tissues
• Used therapeutically in psoriasis (induces keratinocyte differentiation)

4. Immune Function

• Regulates T-lymphocyte and B-lymphocyte function
• Promotes differentiation of monocyte precursors
• Inhibits production of interleukins by activated T cells → anti-inflammatory
• Deficiency associated with ↑risk of autoimmune diseases (MS, T1DM, IBD)

5. Endocrine Effects

• Regulates insulin secretion from pancreatic β-cells
• Involved in parathyroid and thyroid hormone synthesis and secretion
• Deficiency linked to metabolic syndrome, insulin resistance, obesity

---

VI. DEFICIENCY

In Children: RICKETS

In Adults: OSTEOMALACIA

• Demineralization of already formed bone (bone matrix present but unmineralized)
• Bone pain and tenderness (diffuse, especially pelvis, lower back, legs)
• Proximal muscle weakness (myopathy) - very common
• Waddling gait
• Pathological fractures (low-trauma fractures)
• Looser zones (pseudofractures) on X-ray: radiolucent bands perpendicular to bone cortex
• Biochemistry: ↓Ca²⁺, ↓PO₄³⁻, ↑ALP, ↑PTH, ↓25-OH-D₃

High-Risk Groups for Vitamin D Deficiency:

• Premature infants (stores only transferred in last trimester)
• Dark-skinned individuals (melanin blocks UV-B)
• Elderly (↓7-dehydrocholesterol in skin; less outdoor exposure)
• People with malabsorption (celiac, Crohn's, short bowel syndrome)
• Patients on anticonvulsants (accelerated vitamin D catabolism)
• Chronic kidney disease (↓1-hydroxylase activity → cannot make calcitriol)
• Persons with limited sun exposure (veiled women, housebound, night workers)
• Obese individuals (vitamin D sequestered in fat)

---

VII. TOXICITY (Hypervitaminosis D)

• Vitamin D is the most toxic of all fat-soluble vitamins (low therapeutic index)
• Toxicity ONLY occurs with supplements (excess sun exposure converts excess D₃ to inactive forms in skin - self-regulating)
• Toxic dose: chronic > 100 μg/day (4,000 IU) in adults; some infants sensitive at 50 μg/day

---

COMPARATIVE SUMMARY TABLE

---

• Lippincott's Illustrated Reviews: Biochemistry, 8th Ed. - Chapter 28
• Harper's Illustrated Biochemistry, 32nd Ed. - Chapter 44
• Harrison's Principles of Internal Medicine, 22nd Ed. - Chapter on Vitamins
• Tietz Textbook of Laboratory Medicine, 7th Ed. - Chapter 46